3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-(4-tert-butylphenoxy)-propionic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-(4-tert-butylphenoxy)-propionic acid
• 英文别名: 2-(4-tert-butylphenoxy)-2-methyl-3-[4-[2-[5-methyl-2-(3-phenylphenyl)-1,3-oxazol-4-yl]ethoxy]phenyl]propanoic acid
• 化学式: C₃₈H₃₉NO₅
• 分子量: 589.731
• InChiKey: XLIQVPZXRKMXIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.4
• 重原子数：
  44
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  81.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  [2-(3-bromophenyl)-5-methyloxazole-4-yl]-acetonitrile 在 吡啶 、 4-二甲氨基吡啶 、 palladium diacetate 、 氢氧化钾 、 sodium hydroxide 、 硼烷 、 caesium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 乙二醇甲醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-{4-[2-(2-Biphenyl-3-yl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-(4-tert-butylphenoxy)-propionic acid
  参考文献：
  名称：

  Conversion of human-selective PPARα agonists to human/mouse dual agonists: a molecular modeling analysis

  摘要：

  To understand the species selectivity in a series of a-methyl-a-phenoxy carboxylic acid PPARalpha/gamma dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARalpha. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARalpha leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARalpha agonist to a human and mouse dual agonist within the same platform.(C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.09.031

文献信息

• Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
  申请人：——

  公开号：US20040138277A1

  公开（公告）日：2004-07-15

  1 Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

  对PPAR受体进行调节的新型化合物，以及其药用盐、溶剂合物和水合物，制备这些化合物的过程，含有这些化合物或其药用盐、溶剂合物和水合物的药物组合物。
• [EN] OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS<br/>[FR] DÉRIVÉS D'ACIDE OXAZOLYL-ARYLPROPIONIQUE ET LEUR UTILISATION COMME AGONISTES DES PPAR
  申请人：LILLY CO ELI

  公开号：WO2002016332A1

  公开（公告）日：2002-02-28

  Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof.

  一种调节PPAR受体的新型化合物，以及其药学上可接受的盐、溶剂化物和水合物，制备该化合物的方法，含有该化合物或其药学上可接受的盐、溶剂化物和水合物的药物组合物。
• Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
  申请人：Eli Lilly and Company

  公开号：US07176224B2

  公开（公告）日：2007-02-13

  Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereof

  小说化合物是PPAR受体调节剂，以及其药学上可接受的盐、溶剂和水合物，制备这些化合物的过程，含有这些化合物或其药学上可接受的盐、溶剂和水合物的药物组合物。
• OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1313717B1

  公开（公告）日：2007-10-17
• US7176224B2
  申请人：——

  公开号：US7176224B2

  公开（公告）日：2007-02-13